222 related articles for article (PubMed ID: 36398467)
1. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
Kragh N; Tytula A; Pochopien M; Aballéa S; Toumi M; Hakimi Z; Nazir J; Bystrická L; Fatoye F
Eur J Haematol; 2023 Mar; 110(3):262-270. PubMed ID: 36398467
[TBL] [Abstract][Full Text] [Related]
2. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison.
Hakimi Z; Santagostino E; Postma MJ; Nazir J
Adv Ther; 2021 Feb; 38(2):1263-1274. PubMed ID: 33377987
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
Lorenzoni V; Triulzi I; Turchetti G
BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
[TBL] [Abstract][Full Text] [Related]
4. Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe.
Mancuso ME; Castaman G; Pochopien M; Aballéa S; Drzewiecka A; Hakimi Z; Nazir J; Fatoye F
J Med Econ; 2022; 25(1):1068-1075. PubMed ID: 35993970
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.
Klamroth R; Wojciechowski P; Aballéa S; Diamand F; Hakimi Z; Nazir J; Abad-Franch L; Lethagen S; Santagostino E; Tarantino MD
J Blood Med; 2021; 12():115-122. PubMed ID: 33664606
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
[TBL] [Abstract][Full Text] [Related]
7. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
[TBL] [Abstract][Full Text] [Related]
9. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.
Lee H; Cho H; Han JW; Kim AY; Park S; Lee M; Cho S; Baik D; Kang HY
Haemophilia; 2021 Jan; 27(1):e12-e21. PubMed ID: 32894895
[TBL] [Abstract][Full Text] [Related]
11. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
[TBL] [Abstract][Full Text] [Related]
12. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
14. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
[TBL] [Abstract][Full Text] [Related]
15. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
Miners AH; Krishnan S; Pasi KJ
J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor VIII Fc for the treatment of haemophilia A.
Hermans C; Mancuso ME; Nolan B; Pasi KJ
Eur J Haematol; 2021 Jun; 106(6):745-761. PubMed ID: 33650192
[TBL] [Abstract][Full Text] [Related]
17. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
Oldenburg J; Hay CRM; Jiménez-Yuste V; Peyvandi F; Schved JF; Szamosi J; Winding B; Lethagen S
BMJ Open; 2019 May; 9(5):e028012. PubMed ID: 31152037
[TBL] [Abstract][Full Text] [Related]
18. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.
Yu JK; Wong WWL; Keepanasseril A; Iorio A; Edginton AN
Haemophilia; 2023 Mar; 29(2):488-497. PubMed ID: 36528890
[TBL] [Abstract][Full Text] [Related]
20. Real-world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe.
Blatný J; Nielsen EM; Reitzel SB; McMillan AC; Danø A; Bystrická L; Kragh N; Klamroth R
Haemophilia; 2023 Jul; 29(4):963-974. PubMed ID: 37243934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
